一种α和β血红蛋白链的异构体作为一种先天的抗癌剂起作用
Maharrish Chelladurai1, Dan Xu2, Sivan Izraely1
1The Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Science, Tel Aviv University, Tel Aviv, Israel.
一个由α和β链组成的血红蛋白二元体,作为一种来自大脑的因子,抑制黑色素瘤大脑转移. 这种二聚体抑制了癌细胞的增殖,并诱导了亡和亡,为转移性癌症提供了潜在的抵抗因子.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 瘤微环境含有支持转移的因素和反转移的因素.
- 这些因素的平衡决定了癌细胞的扩散和生存.
- 之前的工作确定了血红蛋白β子单元 (HBB) 作为肺衍生的抗转移因子.
研究的目的:
- 研究抑制黑色素瘤大脑转移 (MBM) 的脑衍生因素.
- 为了确定负责这些抗转移效应的分子成分.
- 阐明这些因素影响MBM细胞活力和进展的机制.
主要方法:
- 从MBM中净化来自大脑的因素.
- 对MBM细胞的抗增殖,亡和亡效应的评估.
- 血红蛋白α/β链二元体的化学净化.
- 用二聚体处理的MBM细胞的蛋白质组分析以确定下调的蛋白质.
主要成果:
- 血红蛋白α和β链的异构体被确定为MBM的强有力的抑制剂.
- 双相显著降低了细胞活力,诱导DNA损伤,细胞循环停止 (SubG1),细胞亡和亡在MBM细胞系.
- 单独的α或β子单元都没有表现出抑制活性.
- 蛋白质组分析显示,在经二聚体处理的细胞中,BRD4,GAB2和IRS2蛋白的下调.
结论:
- 一种血红蛋白α/β二聚体是一种新型的来自大脑的抗转移因子.
- 这种二倍体通过诱导细胞死亡和阻止细胞循环进展来抑制MBM.
- 双重体的机制涉及降低BRD4,GAB2和IRS2等关键蛋白质的调节,这表明它作为抗脑转移癌症的抵抗因子的作用.
更多相关视频
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
09:53Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
Published on: February 6, 2017
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Hemoglobin
When all four heme groups are bound to oxygen, the resulting molecule is called oxyhemoglobin. As a result, arterial blood...
Multiple Allele Traits
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Mitogens and the Cell Cycle
